Results. Persistent expression of Hoxa2 in chondrogenic territories
provokes a general down-regulation of several factors known to control the endochondral differentiation cascade, i.e. Sox9, Bapx1, Bmp7, Bmpr1a, Msx1, Pax9, Sox6 and Wnt5a. Furthermore, later molecular agents, such as Ihh and Runx2, are also reduced. As a consequence, Hoxa2 misregulation in mice, which induces a proportionate short stature phenotype mimicking human idiopathic conditions, is associated with a decrease of factors whose effects are distributed along the endochondral ossification cascade.
Materials and methods.
In our transgenic mice (Col2a1/Hoxa2-lacZ; Fig. 2 ), Hoxa2 expression was induced in Col2a1 expressing territories and maintained thereafter, i.e. all over the endochondral bone elements. Mice bearing the hβ-actin-lox-STOP-lox-Hoxa2-lacZ transgene only (βS-Hoxa2-lacZ) were considered controls.
Conclusions.
Our results reveal molecular mechanisms linking the activity of Hoxa2 to a negative impact on endochondral skeleton development (Fig. 4) . These data give insights for understanding idiopathic proportionate short stature pathogenesis.
Objective. The molecular pathways underlying the human idiopathic proportionate short stature (PSS) pathogenesis are still unknown. With our murine transgenic model, we here tried to identify the impact of Hoxa2 overexpression on the main factors involved in endochondral ossification in order to evaluate their possible role in idiopathic PSS. Using immunohistochemistry and Western blotting, we compared the protein levels of Bapx1, Runx2, Sox5, Sox6, Bmpr1a, Foxc2, β1-integrin, Bmp7, Gdf10, Gdf5, Ihh, Wnt5a, Gdf3, Bmp4, Fgfr3, Gdf6, Meox1, Meox2, Pax1, PthrP, Msx1, Msx2, Osteopontin, Pax9, S-100 and Sox9 in E13.5, E15.5 and E16.5 transgenic and control mice. Immunohistochemistry was performed on sagittal paraffin sections through the spine. 
